pt141 huberman Dr. Craig Koniver: Peptide & Hormone Therapies for Health, Performance & Longevity AG1® | Andrew Huberman x

Finally, BODIPY 581/591 staining showed that MK-7 did not reduce RSL3-induced lipid peroxidation in VKORC1L1-silenced cells (Fig

SS-31 10mg Vial Best for: Short-term protocols (2-4 weeks) or testing tolerance Reconstitution: 1.0 mL bacteriostatic water 10 mg/mL concentration Dosing at 10 mg/mL: 1 unit = 0.01 mL = 100 mcg 10 mg dose: 100 units (1.0 mL) Vials needed for 8 weeks @ 10mg/day: 50 vials SS-31 30mg Vial Best for: Standard 8-12 week protocols Reconstitution: 3.0 mL bacteriostatic water ~10 mg/mL concentration Dosing at 10 mg/mL: 1 unit = 0.01 mL = 100 mcg 10 mg dose: 100 units (1.0 mL) Vials needed for 8 weeks @ 10mg/day: 17 vials SS-31 50mg Vial Best for: Extended protocols or costeffective bulk research Reconstitution: 3.0 mL bacteriostatic water ~16.67 mg/mL concentration Dosing at 16.67 mg/mL: 1 unit = 0.01 mL 167 mcg 10 mg dose: 60 units (0.60 mL) Vials needed for 8 weeks @ 10mg/day: 10 vials Dosing & Reconstitution Guide Educational guide for reconstitution and daily dosing across all vial sizes Standard / Gradual Approach Frequency: Inject once daily subcutaneously at a consistent time

doi: 10.1186/1472-6882-8-63

Chi-square test of independence: For the association between qualitative variables, the Chi-square test of independence was used